QurAlis

QurAlis Corporation is a clinical-stage biotechnology company founded on December 12, 2016 in Cambridge, Massachusetts by Drs. Kasper Roet, Kevin Eggan and Clifford Woolf together with Q-State Biosciences, and staffed by neurodegenerative biologists out of Harvard Medical School and Harvard University. The company develops precision medicines for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and other neurodegenerative and neurological diseases, built on the discovery — published in Nature Neuroscience by co-founder Kevin Eggan's lab — that loss of normal TDP-43 function drives a decrease in STATHMIN-2 (STMN2) expression and impairs neuronal repair. Its lead candidates are QRL-201, a first-in-class molecule intended to restore STMN2 expression in ALS (ANQUR trial), and QRL-101, a potentially best-in-class selective Kv7.2/7.3 ion channel opener for hyperexcitability-induced disease progression in ALS as well as epilepsy and pain; a third program targets UNC13A cryptic-exon mis-splicing. Therapies are built on the proprietary FlexASO® anti-sense oligonucleotide splice-modulator platform. QurAlis publishes a corporate site covering its story, pipeline, platform, people, patient resources, presentations and press releases, but runs no developer program: no API documentation, no SDKs, no developer portal, no GitHub organisation and no machine-readable API contract of any kind.

QurAlis is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Neurology.

QurAlis’ developer surface includes product news, engineering blog, support, and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub
12.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesNeurologyNeurodegenerative DiseaseALSPrecision MedicineClinical TrialsDrug DevelopmentHealthcare

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 12.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 1.1 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/quralis: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Quralis Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown
WellKnown
 LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 7

The organization behind the API

Website
Website
 About
About
 Careers
Careers
 News
News
 Blog
Blog
 LinkedIn
LinkedIn
 Twitter
Twitter

Scroll for all 7

Other 6

Properties that don't map to a standard resource type

Pipeline
Pipeline
 Platform
Platform
 Team
Team
 Patients
Patients
 Publications
Publications
 SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: quralis
name: QurAlis
image: https://www.quralis.com/wp-content/uploads/2024/04/Quralis_Square_ogThumbnail_Royal_Blue_RGB.png
description: 'QurAlis Corporation is a clinical-stage biotechnology company founded on December 12, 2016 in Cambridge, Massachusetts
  by Drs. Kasper Roet, Kevin Eggan and Clifford Woolf together with Q-State Biosciences, and staffed by neurodegenerative
  biologists out of Harvard Medical School and Harvard University. The company develops precision medicines for amyotrophic
  lateral sclerosis (ALS), frontotemporal dementia (FTD) and other neurodegenerative and neurological diseases, built on the
  discovery — published in Nature Neuroscience by co-founder Kevin Eggan''s lab — that loss of normal TDP-43 function drives
  a decrease in STATHMIN-2 (STMN2) expression and impairs neuronal repair. Its lead candidates are QRL-201, a first-in-class
  molecule intended to restore STMN2 expression in ALS (ANQUR trial), and QRL-101, a potentially best-in-class selective Kv7.2/7.3
  ion channel opener for hyperexcitability-induced disease progression in ALS as well as epilepsy and pain; a third program
  targets UNC13A cryptic-exon mis-splicing. Therapies are built on the proprietary FlexASO® anti-sense oligonucleotide splice-modulator
  platform. QurAlis publishes a corporate site covering its story, pipeline, platform, people, patient resources, presentations
  and press releases, but runs no developer program: no API documentation, no SDKs, no developer portal, no GitHub organisation
  and no machine-readable API contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/quralis/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Neurology
- Neurodegenerative Disease
- ALS
- Precision Medicine
- Clinical Trials
- Drug Development
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.quralis.com/
- type: About
  url: https://www.quralis.com/our-story/
- type: Pipeline
  url: https://www.quralis.com/pipeline/
- type: Platform
  url: https://www.quralis.com/platforms/
- type: Team
  url: https://www.quralis.com/people/
- type: Careers
  url: https://www.quralis.com/culture/
- type: Patients
  url: https://www.quralis.com/patients/
- type: Publications
  url: https://www.quralis.com/presentations-and-publications/
- type: News
  url: https://www.quralis.com/news/
- type: Blog
  url: https://www.quralis.com/news/
- type: Support
  url: https://www.quralis.com/contact/
- type: PrivacyPolicy
  url: https://www.quralis.com/privacy-policy/
- type: TermsOfService
  url: https://www.quralis.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/quralis1/
- type: Twitter
  url: https://twitter.com/QurAlisCo
- type: SecondaryMarket
  url: https://forgeglobal.com/quralis_stock/
- type: DomainSecurity
  url: security/quralis-domain-security.yml
- type: WellKnown
  url: well-known/quralis-well-known.yml
- type: LLMsTxt
  url: llms/quralis-llms.txt
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: QurAlis is a clinical-stage biopharmaceutical company whose product is a drug pipeline, not software — no api.,
    developer., docs., portal. or data. host resolves for quralis.com, no quralis GitHub organisation or npm/PyPI package
    exists, and every /.well-known/ and spec path on www.quralis.com returns a clean 404, leaving only the marketing site's
    WordPress /wp-json/ CMS routes whose bundled MCP and Abilities endpoints answer anonymous callers with 401 rest_forbidden.
  evidence:
  - url: https://www.quralis.com/openapi.json
    status: 404
  - url: https://www.quralis.com/.well-known/agent-card.json
    status: 404
  - url: https://www.quralis.com/llms.txt
    status: 404
  - url: https://www.quralis.com/wp-json/mcp/mcp-adapter-default-server
    status: 401
  - url: https://api.github.com/orgs/quralis
    status: 404
  checked: '2026-08-05'